BOSTON, Mass., April 29, 2019 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced it will present one poster on CNTX-4975 at the 2019 British Society for Rheumatology (BSR) Annual Conference taking place April 30-May 2, 2019 in Birmingham, UK and four posters on CNTX-4975 at the Osteoarthritis Research Society International (OARSI) 2019 World Congress taking place May 2-5, 2019 in Ontario, Canada.

“We have continued to make significant advances in refining our proprietary cooling procedure technique for intra-articular injection of CNTX-4975 for painful knee osteoarthritis, and are pleased to report in these posters a nearly 50% reduction in procedure time. We have demonstrated the maintenance of the lowered joint temperature for 30 minutes after removal of the cooling wrap. Importantly, even with the shortened procedure time, patient comfort is maintained,” said Dr. Randall Stevens, chief medical officer of Centrexion. “Our initial procedure technique was conservative and designed with an emphasis on ensuring the blinding of our clinical trials. We continue to conduct additional studies to optimize the cooling procedure to meet the needs of patients and clinicians in medical practice settings and look forward to reporting additional new data at EULAR in June.”

Full abstracts have been published in *Rheumatology* and are available online at [https://academic.oup.com/rheumatology](https://academic.oup.com/rheumatology). Details of the poster presentation are listed below.

**Title:** Evaluation of Intra-articular CNTX-4975 (Highly Purified, Synthetic trans-Capsaicin) for Knee Osteoarthritis (OA) Pain in Subjects With Radiographic Presence of OA in the Opposite Knee  
**Session Title:** Wednesday Poster Viewing  
**Poster Number:** 161  
**Presentation Time:** Wednesday, May 1, 9:00AM – 5:00PM  
**Location:** The ICC, Birmingham - Halls 3 and 4

Full abstracts have been published in *Osteoarthritis & Cartilage* and are available online at [https://www.oarsijournal.com](https://www.oarsijournal.com). Details of the poster presentations are listed below.

**Title:** Effects of Skin Cooling on Intra-articular Knee Temperature in Health Subjects  
**Session Title:** Poster Session 1 and 2  
**Poster Number:** 708  
**Presentation Time:** Friday, May 3, 4:15PM – 5PM and Saturday, May 4, 4:15PM – 5:00PM  
**Location:** Sheraton Centre Toronto - Sheraton Hall / Osgoode & Foyers

**Title:** Intra-articular CNTX-4975 for Osteoarthritis Knee Pain: Subgroup and Post Hoc Analyses of a Randomized Phase 2 Study  
**Session Title:** Poster Session 1 and 2  
**Poster Number:** 722  
**Presentation Time:** Friday, May 3, 4:15PM – 5PM and Saturday, May 4, 4:15PM – 5:00PM  
**Location:** Sheraton Centre Toronto - Sheraton Hall / Osgoode & Foyers

**Title:** Procedure Pain Associated With Intra-articular Injection of CNTX-4975 for Management of Painful Osteoarthritis of the Knee Varies With Cooling  
**Session Title:** Poster Session 1 and 2  
**Poster Number:** 733
Title: Bilateral Intra-articular Injection of CNTX-4975 for Management of Painful Osteoarthritis of the Knee: Results at 6 Weeks From an Open-label Trial
Session Title: Poster Session 1 and 2
Poster Number: 734
Presentation Time: Friday, May 3, 4:15PM – 5PM and Saturday, May 4, 4:15PM – 5:00PM
Location: Sheraton Centre Toronto - Sheraton Hall / Osgoode & Foyers

About Osteoarthritis
Osteoarthritis (“OA”) is the most common joint disease in the United States, currently affecting more than 30 million Americans, according to the U.S. Centers for Disease Control. OA occurs when cartilage, the tissue that envelops the structural bones within a joint, gradually deteriorates. These changes cause pain, swelling and problems moving the joint. Although OA can affect any joint, it most often affects joints in the knees, hips, lower back and neck, small joints of the fingers and the bases of the thumb and big toe. Over time, patients with knee OA tend to become inactive due to pain and joint stiffness and reduced function.

About CNTX-4975
CNTX-4975, Centrexion’s most advanced product candidate, is an investigational synthetic, ultra-pure intra-articular injection of trans-capsaicin for the treatment of moderate to severe pain associated with knee OA. CNTX-4975 is designed to be administered directly into the joint where the pain stimulus originates and to selectively and locally target and disrupt the signaling of pain-sensing nerve fibers. In January 2018, CNTX-4975 was granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of pain associated with knee OA.

About Centrexion Therapeutics
Centrexion is a late clinical-stage biopharmaceutical company focused on becoming the leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Centrexion’s website address is http://www.centrexion.com.


###

Media Contact
Julie Normart, W2O pure
+1 (559) 974-3245
jnormart@w2ogroup.com

Investor Contact
Courtney Dugan, W2O pure
+1 (212) 257-6723
cdugan@w2ogroup.com